hepatorenal syndrome

Summary

Summary: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.

Top Publications

  1. ncbi Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome
    Aleksander Krag
    Department of Gastroenterology, Hvidovre University Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Adv Ther 25:1105-40. 2008
  2. ncbi MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation
    Carlo Alessandria
    Liver Unit, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
    Hepatology 41:1282-9. 2005
  3. ncbi Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites
    A Krag
    Department of Medical Gastroenterology 439, Hvidovre Hospital, DK 2650 Hvidovre, Denmark
    Gut 59:105-10. 2010
  4. ncbi Hepatorenal syndrome: pathophysiology and management
    Hani M Wadei
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Jacksonville, FL 32216, USA
    Clin J Am Soc Nephrol 1:1066-79. 2006
  5. ncbi Circulatory function and hepatorenal syndrome in cirrhosis
    Luis Ruiz-del-Arbol
    Hepatic Hemodynamic Unit, Gastroenterology Department, Hospital Ramon y Cajal, University of Alcala, Ctra de Colmenar Viejo Km 9 1, 28034 Madrid, Spain
    Hepatology 42:439-47. 2005
  6. ncbi Hepatorenal syndrome
    Pere Gines
    Liver Unit, Hospital Cli nic, Institut d Investigacions Biomèdiques August Pi Sunyer, University of Barcelona School of Medicine, Barcelona, Catalunya, Spain
    Lancet 362:1819-27. 2003
  7. ncbi Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome
    Sergio Neri
    Department of Internal Medicine and Systemic Diseases, Liver Operative Unit, Catania University Polyclinic, Catania 95123, Italy
    Dig Dis Sci 53:830-5. 2008
  8. ncbi Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study
    Richard Moreau
    INSERM U 481 et Service d Hépatologie, Hopital Beaujon, Clichy, France
    Gastroenterology 122:923-30. 2002
  9. pmc A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
  10. ncbi Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study
    Christophe Duvoux
    Service d hépatologie et de gastroentérologie, AP HP, Hopital Henri Mondor, Creteil, France
    Hepatology 36:374-80. 2002

Detail Information

Publications280 found, 100 shown here

  1. ncbi Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome
    Aleksander Krag
    Department of Gastroenterology, Hvidovre University Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Adv Ther 25:1105-40. 2008
    ..used in the treatment of patients with cirrhosis and bleeding esophageal varices (BEV) and in patients with hepatorenal syndrome (HRS): two of the most dramatic and feared complications of cirrhosis...
  2. ncbi MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation
    Carlo Alessandria
    Liver Unit, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
    Hepatology 41:1282-9. 2005
    Important progress has been made recently regarding the pathogenesis and treatment of hepatorenal syndrome (HRS). However, scant information exists about factors predicting outcome in patients with cirrhosis and HRS...
  3. ncbi Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites
    A Krag
    Department of Medical Gastroenterology 439, Hvidovre Hospital, DK 2650 Hvidovre, Denmark
    Gut 59:105-10. 2010
    Recent studies suggest that cardiac dysfunction precedes development of the hepatorenal syndrome. In this follow-up study, we aimed to investigate the relation between cardiac and renal function in patients with cirrhosis and ascites and ..
  4. ncbi Hepatorenal syndrome: pathophysiology and management
    Hani M Wadei
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Jacksonville, FL 32216, USA
    Clin J Am Soc Nephrol 1:1066-79. 2006
  5. ncbi Circulatory function and hepatorenal syndrome in cirrhosis
    Luis Ruiz-del-Arbol
    Hepatic Hemodynamic Unit, Gastroenterology Department, Hospital Ramon y Cajal, University of Alcala, Ctra de Colmenar Viejo Km 9 1, 28034 Madrid, Spain
    Hepatology 42:439-47. 2005
    The pathogenic mechanism of hepatorenal syndrome is not well established. We investigated the circulatory function in cirrhosis before and after the development of hepatorenal syndrome...
  6. ncbi Hepatorenal syndrome
    Pere Gines
    Liver Unit, Hospital Cli nic, Institut d Investigacions Biomèdiques August Pi Sunyer, University of Barcelona School of Medicine, Barcelona, Catalunya, Spain
    Lancet 362:1819-27. 2003
    b>Hepatorenal syndrome (HRS) is a common complication of advanced cirrhosis, characterised by renal failure and major disturbances in circulatory function. Renal failure is caused by intense vasoconstriction of the renal circulation...
  7. ncbi Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome
    Sergio Neri
    Department of Internal Medicine and Systemic Diseases, Liver Operative Unit, Catania University Polyclinic, Catania 95123, Italy
    Dig Dis Sci 53:830-5. 2008
    b>Hepatorenal syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in cirrhotic patients presenting ascites...
  8. ncbi Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study
    Richard Moreau
    INSERM U 481 et Service d Hépatologie, Hopital Beaujon, Clichy, France
    Gastroenterology 122:923-30. 2002
    Type 1 hepatorenal syndrome (HRS) is a severe complication of cirrhosis associated with a short median survival time (<2 weeks). Although the administration of terlipressin improves renal function, its effect on survival is unknown...
  9. pmc A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
    b>Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease...
  10. ncbi Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study
    Christophe Duvoux
    Service d hépatologie et de gastroentérologie, AP HP, Hopital Henri Mondor, Creteil, France
    Hepatology 36:374-80. 2002
    ..5 mg/h NA) that did not recur after a dose reduction. In conclusion, NA combined with albumin and furosemide appears effective and safe for the treatment of type 1 HRS...
  11. ncbi Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
    P Angeli
    Department of Clinical and Experimental Medicine, University of Padua, Padova, Italy
    Hepatology 29:1690-7. 1999
    ..inhibitor of the release of endogenous vasodilators together with a vasoconstrictor agent in patients with hepatorenal syndrome (HRS)...
  12. ncbi Management of hepatorenal syndrome in patients with cirrhosis
    Vicente Arroyo
    Liver Unit, Hospital Clinic Barcelona, University of Barcelona, Villarroel 170, Barcelona, Catalonia 08036, Spain
    Nat Rev Nephrol 7:517-26. 2011
    ..In patients with advanced cirrhosis, these processes culminate in renal vasoconstriction and type 2 hepatorenal syndrome (HRS), which is characterized by slowly progressive renal failure and refractory ascites...
  13. pmc Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis
    Sharanabasayyaswamy B Hiremath
    Department of Pharmacology, SDM College of Medical Sciences and Hospital, Davangere, Karnataka, India
    Indian J Pharmacol 45:54-60. 2013
    Terlipressin improves renal function in hepatorenal syndrome (HRS) is a known fact. However the reason for lack of its long-term survival benefits despite improvement in renal function remains unclear...
  14. pmc Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics
    Thomas D Boyer
    Dept of Medicine, University of Arizona, College of Medicine, Tucson, AZ, United States
    J Hepatol 55:315-21. 2011
    ..However, only about 1/3 of patients respond to treatment, therefore, predictors of response and survival would help identify the patients most likely to benefit from treatment...
  15. ncbi Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study
    Chantal Halimi
    Service d Hepato Gastroenterologie, Centre Hospitalier de Senlis, Paris, France
    Eur J Gastroenterol Hepatol 14:153-8. 2002
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis, leading to death in more than 90% of cases in the absence of liver transplantation. Several treatments have been attempted as a bridge to liver transplantation...
  16. ncbi Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial
    S R Mitzner
    Department of Medicine, University of Rostock, Germany
    Liver Transpl 6:277-86. 2000
    In hepatorenal syndrome (HRS), renal insufficiency is often progressive, and the prognosis is extremely poor under standard medical therapy...
  17. pmc Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
    Mitra K Nadim
    Department of Medicine, University of Southern California, 1520 San Pablo Street, Suite 4300, Los Angeles, CA 90033, USA
    Crit Care 16:R23. 2012
    ..Since the original publication of the definition and diagnostic criteria for the hepatorenal syndrome (HRS), there have been major advances in our understanding of its pathogenesis...
  18. ncbi The use of albumin in all patients with decompensated cirrhosis is not justified
    Benjamin Avidan
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 7:118-20. 2005
  19. ncbi Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis
    Florence Wong
    Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario M5G2C4, Canada
    Gut 60:702-9. 2011
    ..Therefore, there is a need for a newer classification to include both functional and structural renal diseases...
  20. ncbi Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study
    Marta Martín-Llahí
    Liver Unit, Hospital Clinic, University of Barcelona School of Medicine, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Barcelona, Spain
    Gastroenterology 134:1352-9. 2008
    b>Hepatorenal syndrome is common in patients with advanced cirrhosis and constitutes a major problem in liver transplantation. There is no effective medical treatment for hepatorenal syndrome.
  21. ncbi Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome
    Lise L Gluud
    Department of Internal Medicine, Copenhagen University Hospital Gentofte, Hellerup, Denmark
    Hepatology 51:576-84. 2010
    Vasoconstrictor drugs may improve renal function in hepatorenal syndrome (HRS), but the effect on mortality has not been established...
  22. ncbi Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS
    Mohamad R Al Sibae
    Division of Transplantation, Department of Surgery, William Beaumont Hospital, Royal Oak, MI 48073, USA
    Dig Dis Sci 56:977-87. 2011
    ....
  23. ncbi Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT)
    Richard Ruiz
    Baylor Regional Transplant Institute, Dallas, TX 75246, USA
    Liver Transpl 13:838-43. 2007
    b>Hepatorenal syndrome (HRS) is a well-recognized complication of end-stage liver disease...
  24. ncbi Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome
    Eric Esrailian
    Division of Digestive Diseases, David Geffen School of Medicine at UCLA, USA
    Dig Dis Sci 52:742-8. 2007
    Type 1 hepatorenal syndrome (HRS) can be a rapidly fatal consequence of liver failure. Recent studies have utilized vasoconstrictor therapies to combat splanchnic vasodilatation...
  25. pmc Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
    Francesco Salerno
    Department of Internal Medicine, Policlinico IRCCS San Donato, University of Milan, Via Morandi, 30, 20097 San Donato MI, Italy
    Gut 56:1310-8. 2007
  26. ncbi Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites
    Andreas Umgelter
    II Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Ismaninger Str 22, 81675, Munich, Germany
    Intensive Care Med 35:152-6. 2009
    ..To assess the effect of reducing intra-abdominal pressure (IAP) by paracentesis on renal resistive index (RI), hemodynamics and renal function...
  27. ncbi An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response
    Praveen Sharma
    Department of Gastroenterology, G B Pant Hospital, New Delhi, India
    Am J Gastroenterol 103:1689-97. 2008
    b>Hepatorenal syndrome (HRS) is characterized by functional renal failure in end-stage liver disease. Terlipressin is the drug of choice for treating type 1 HRS (HRS-1). It is expensive and often not readily available...
  28. ncbi Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study
    Virendra Singh
    Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    J Hepatol 56:1293-8. 2012
    Various vasoconstrictors are useful in the management of hepatorenal syndrome (HRS). Terlipressin is the drug of choice; however, it is expensive...
  29. pmc Hepatorenal syndrome
    Jan Lata
    Department of Internal Medicine, University Hospital and Faculty of Medicine, Ostrava University, 70103 Ostrava, Czech Republic
    World J Gastroenterol 18:4978-84. 2012
    b>Hepatorenal syndrome (HRS) is defined as a functional renal failure in patients with liver disease with portal hypertension and it constitutes the climax of systemic circulatory changes associated with portal hypertension...
  30. ncbi Terlipressin in hepatorenal syndrome: Evidence for present indications
    Harshal Rajekar
    Department of General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
    J Gastroenterol Hepatol 26:109-14. 2011
    b>Hepatorenal syndrome (HRS) is the most frequent life threatening complication of advanced liver failure and cirrhosis...
  31. ncbi Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study
    Jean Marie Peron
    Service d Hepato gastro enterologie, Fédération Digestive, Hopital Purpan, Toulouse, France
    Am J Gastroenterol 100:2702-7. 2005
    b>Hepatorenal syndrome (HRS) is a functional renal failure that occurs late during cirrhosis. The prognosis is extremely poor with a mean survival of 1.7 wks from the time of diagnosis...
  32. ncbi Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome
    A Di Micoli
    Department of Internal Medicine, Cardioangiology and Hepatology, Alma Mater Studiorum, University of Bologna, Bologna, Italy
    Dig Liver Dis 40:304-5. 2008
    We report a case of a 65-year-old woman with hepatitis C virus-related decompensated cirrhosis with hepatorenal syndrome, treated by high dose of terlipressin...
  33. ncbi Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study
    Saubhik Ghosh
    Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Liver Int 33:1187-93. 2013
    Various vasoconstrictors have shown promising results in the management of type 1 hepatorenal syndrome (HRS). However, there are very few studies on vasopressors in the management of type 2 HRS...
  34. ncbi Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis
    Mattias Mandorfer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria Vienna Hepatic Hemodynamic Lab, Vienna, Austria
    Gastroenterology 146:1680-90.e1. 2014
    ..We investigated the effects of NSBBs in patients with cirrhosis and ascites with and without SBP...
  35. pmc Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis
    Mirela Dobre
    Department of Medicine, Huron Hospital A Cleveland Clinic Hospital, Cleveland, OH, USA
    Int Urol Nephrol 43:175-84. 2011
    b>Hepatorenal syndrome (HRS) is a common complication in patients with cirrhosis or fulminant liver failure. We systematically reviewed the benefits and harms of using terlipressin, a novel vasoconstricting agent in patients with HRS.
  36. ncbi Diagnostic significance of nitrates and nitrites and L-arginine, in development of hepatorenal syndrome in patients with end stage alcoholic liver cirrhosis
    Vanja Nicković
    Faculty of Medicine, Pristina Kosovska Mitrovica, Kosovska Mitrovica, Serbia
    Ren Fail 35:633-9. 2013
    b>Hepatorenal syndrome (HRS) represents a complication of the end-stage liver cirrhosis...
  37. ncbi Meta-analysis: terlipressin therapy for the hepatorenal syndrome
    F Fabrizi
    Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS, Milan, Italy
    Aliment Pharmacol Ther 24:935-44. 2006
    The hepatorenal syndrome is a severe and well-known complication of end-stage liver disease, but its management is controversial...
  38. ncbi Terlipressin for hepatorenal syndrome
    Lise Lotte Gluud
    Department of InternalMedicine, Gentofte Universityhospital, Hellerup, Denmark
    Cochrane Database Syst Rev 9:CD005162. 2012
    Clinical trials suggest that terlipressin improves renal function in hepatorenal syndrome, but the evidence concerning mortality is equivocal.
  39. ncbi Increased production of cysteinyl leukotrienes in hepatorenal syndrome
    K P Moore
    Liver Unit, King s College Hospital, Denmark Hill, London, United Kingdom
    J Hepatol 11:263-71. 1990
    ..which may modulate glomerular function in vivo, and may therefore be important in the pathogenesis of hepatorenal syndrome. Urinary leukotriene E4, the major metabolite of leukotrienes C4 and D4, was elevated in patients with ..
  40. ncbi Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1
    Andreas Umgelter
    II Medizinische Klinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaninger Str 22 D 81675 Munich, Germany
    Ann Hepatol 11:232-9. 2012
    b>Hepatorenal syndrome type I (HRS I) may be a consequence of circulatory dysfunction in cirrhotic patients with portal hypertension...
  41. ncbi Hepatorenal syndrome: are we missing some prognostic factors?
    Marco Olivera-Martinez
    Section of Gastroenterology and Hepatology, University of Nebraska Medical Center, 983040 Nebraska Medical Center, Omaha, NE 69198 3040, USA
    Dig Dis Sci 57:210-4. 2012
    b>Hepatorenal syndrome (HRS) is the functional renal failure associated with advanced cirrhosis and has also been described in fulminant hepatic failure. Without liver transplantation its prognosis is dismal...
  42. ncbi The Prometheus device for extracorporeal support of combined liver and renal failure
    Kinan Rifai
    Division of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Blood Purif 23:298-302. 2005
    ..Therefore, it is a promising treatment option for patients with hepatorenal syndrome (HRS).
  43. ncbi Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice
    Francesco Salerno
    Policlinico IRCCS San Donato, University of Milan, Italy
    J Hepatol 55:1241-8. 2011
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis with ascites. The International Ascites Club recommended strict diagnostic criteria and treatment with vasoconstrictors and albumin...
  44. ncbi Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study
    C Alessandria
    Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Torino, Italy
    J Hepatol 47:499-505. 2007
    Treatment of hepatorenal syndrome (HRS) is based on vasoconstrictors. Terlipressin is the one with the soundest evidence. Noradrenalin has been suggested as an effective alternative...
  45. ncbi Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice
    Paolo Angeli
    Department of Medicine, Unit of Hepatic Emergencies and Liver Transplantation, University of Padova, Italy
    J Hepatol 57:1135-40. 2012
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis that is associated with poor survival...
  46. ncbi Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation
    Gianni Testino
    Unit of Hepato Gastroenterology Monoblocco 12, S Martino Hospital, Piazzale R Benzi 16132, Genova, Italy
    Hepatogastroenterology 50:1753-5. 2003
    ..Its role in the management of refractory ascites and hepatorenal syndrome still awaits further prospective studies. Type-2 hepatorenal syndrome is a moderate steady renal impairment...
  47. ncbi Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis
    Vanja Nicković
    Faculty of Medicine, University of Pristina Kosovska Mitrovica, Kosovska Mitrovica, Serbia
    Vojnosanit Pregl 69:686-91. 2012
    ..b>Hepatorenal syndrome (HRS) is the most severe complication of alcoholic liver cirrhosis...
  48. pmc Severe acute alcoholic hepatitis and hepatorenal syndrome: role of transjugular intrahepatic portosystemic stent shunt
    G Testino
    Department of Specialist Medicine, S Martino Hospital, Genoa, Italy
    J Med Life 5:203-5. 2012
    ..to different factors: liver failure, severe infections, and portal hypertension with variceal bleeding and hepatorenal syndrome (HRS)...
  49. ncbi Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study
    Tyree H Kiser
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO, USA
    Nephrol Dial Transplant 20:1813-20. 2005
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis and is associated with high mortality. Ornipressin and terlipressin are effective in treatment of HRS, but are not available in the USA...
  50. ncbi Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome
    Florence Wong
    Division of Gastroenterology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Canada
    Hepatology 47:160-8. 2008
    Renal vasoconstriction is a key factor in the development of hepatorenal syndrome (HRS) and may be secondary to increased activities of endothelin-1, a potent renal vasoconstrictor...
  51. ncbi Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels
    Yeon Seok Seo
    Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
    Liver Int 29:1521-7. 2009
    ..This study evaluated the clinical significance of CysC in patients with cirrhotic ascites and a normal serum Cr level...
  52. ncbi [Intrarenal arterial doppler ultrasonography in cirrhotic patients with ascites, with and without hepatorenal syndrome]
    Alberto Bardi
    Centro de Gastroenterología y Unidad de Nefrología, Departamento de Medicina y Servicio de Radiología, Hospital Clinico Universidad de Chile
    Rev Med Chil 130:173-80. 2002
    The pathophysiological hallmark of the hepatorenal syndrome (HRS) is renal vasoconstriction...
  53. ncbi Recent advances in our understanding of hepatorenal syndrome
    Florence Wong
    Toronto General Hospital, University of Toronto, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
    Nat Rev Gastroenterol Hepatol 9:382-91. 2012
    b>Hepatorenal syndrome (HRS) is a serious complication of advanced cirrhosis with ascites. HRS develops as a result of abnormal haemodynamics, leading to splanchnic and systemic vasodilatation, but renal vasoconstriction...
  54. ncbi Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials
    P Tandon
    Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Aliment Pharmacol Ther 25:1017-28. 2007
    Although reversal of pretransplant renal dysfunction in hepatorenal syndrome reduces post-transplant complications, the overall impact on morbidity and mortality requires clarification.
  55. ncbi Hepatorenal syndrome
    Monica Guevara
    Hospital Clinic Barcelona, Liver Unit, IDIBAPS, CIBERHED, Barcelona, Spain
    Expert Opin Pharmacother 12:1405-17. 2011
    ..Renal failure in cirrhosis is a common complication that is associated with poor survival. A rapid diagnosis of the cause of renal failure is mandatory because it is associated with prognosis...
  56. ncbi The role of duplex-doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis
    Snijezana Kastelan
    Department of Gastroenterology, Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia
    Hepatogastroenterology 51:1408-12. 2004
    ..measured by duplex-Doppler ultrasonography for detecting early impairment of renal function in patients with liver cirrhosis and its possible use in detecting a subgroup of patients with a higher risk of developing hepatorenal syndrome.
  57. ncbi Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome
    Aleksander Krag
    Department of Gastroenterology, Hvidovre Hospital, Denmark
    Hepatology 46:1863-71. 2007
    ..The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS)...
  58. ncbi Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome
    Catherine Skagen
    Section of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Clin Gastroenterol 43:680-5. 2009
    Few therapeutic modalities exist for the treatment of hepatorenal syndrome (HRS)...
  59. ncbi Hepatorenal syndrome: a dreaded complication of end-stage liver disease
    Andres Cardenas
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Boston, MA 02215, USA
    Am J Gastroenterol 100:460-7. 2005
    b>Hepatorenal syndrome is the dreaded complication of end-stage liver disease characterized by functional renal failure due to renal vasoconstriction in the absence of underlying kidney pathology...
  60. ncbi [Hepatorenal syndrome in patients with liver cirrhosis]
    Stéphane Zaza
    Division des soins intensifs, Departement de Medecine Interne, CHU Vaudois, Rue du Bugnon 11, 1011 Lausanne, Switzerland
    Nephrol Ther 1:174-82. 2005
    b>Hepatorenal syndrome is a particular form of functional renal failure which may develop in patients with liver cirrhosis...
  61. ncbi Review article: albumin in the treatment of liver diseases--new features of a classical treatment
    V Arroyo
    Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, Spain
    Aliment Pharmacol Ther 16:1-5. 2002
    ..have clearly demonstrated its efficacy in the prevention and treatment of circulatory dysfunction and hepatorenal syndrome in patients with cirrhosis...
  62. ncbi Hepatorenal syndrome: a review
    Gianni Testino
    Unit of Alcoholic Diseases and Hepatology, Department of Specialistic Medicine, San Martino Hospital, Genova, Italy
    Hepatogastroenterology 57:1279-84. 2010
    b>Hepatorenal Syndrome (HRS) is a serious and life-threatening complication of portal hypertension and end stage liver disease...
  63. ncbi Terlipressin and albumin combination treatment in hepatorenal syndrome
    Ahmet Danalioglu
    Istanbul University, Istanbul Medical Faculty, Gastroenterohepatology Department, Turkey
    Hepatogastroenterology 50:ccciii-cccv. 2003
    b>Hepatorenal syndrome (HRS) is a severe complication of cirrhosis, leading to death in nearly all of cases in the absence of liver transplantation. Several treatments have been attempted as a bridge to liver transplantation...
  64. ncbi Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study
    C Alessandria
    Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Turin, Italy
    Dig Liver Dis 41:298-302. 2009
    b>Hepatorenal syndrome is a severe complication of cirrhosis. Treatment with terlipressin has currently the best efficacy pedigree, inducing hepatorenal syndrome reversal in a high proportion of patients...
  65. ncbi Single pass albumin dialysis in hepatorenal syndrome
    Ebadur Rahman
    Department of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia
    Saudi J Kidney Dis Transpl 19:479-84. 2008
    b>Hepatorenal syndrome (HRS) is the most appalling complication of acute or chronic liver disease with 90% mortality rate. Single pass albumin dialysis (SPAD) can be considered as a noble liver support technique in HRS...
  66. ncbi Type-1 hepatorenal syndrome in patients with alcoholic end stage liver disease listed for liver transplantation: role of transjugular intrahepatic portosystemic stent shunt
    G Testino
    Panminerva Med 49:43-5. 2007
  67. ncbi Management of refractory ascites and hepatorenal syndrome
    Amy N Sussman
    Department of Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Curr Gastroenterol Rep 13:17-25. 2011
    ..Lastly, the development of hepatorenal syndrome indicates the patient's liver disease is advanced, and transplantation again is the best option...
  68. ncbi Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome
    Adam G Testro
    Department of Gastroenterology and Liver Transplantation, Austin Hospital, Heidelberg, Victoria, Australia
    J Gastroenterol Hepatol 23:1535-40. 2008
    Studies suggest that terlipressin is effective in the treatment of hepatorenal syndrome (HRS). However, factors predicting response to therapy and the long-term outcome of patients have not been defined.
  69. ncbi Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis
    Claudia Fagundes
    Liver Unit, Hospital Clinic and University of Barcelona School of Medicine, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Ciber de Enfermedades Hepáticas y Digestivas CIBERHED, Insituto Reina Sofia de Investigación Nefrológica IRSIN, Barcelona, Catalunya, Spain
    Am J Kidney Dis 59:874-85. 2012
    b>Hepatorenal syndrome (HRS) is a unique type of kidney failure that occurs in advanced cirrhosis...
  70. ncbi Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis
    Beate Appenrodt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Eur J Gastroenterol Hepatol 21:1428-32. 2009
    b>Hepatorenal syndrome (HRS) is a frequent complication of end-stage liver cirrhosis. HRS type I has a very poor prognosis...
  71. ncbi Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels
    Hyung Su Ahn
    Department of Internal Medicine, Chun Hyang University College of Medicine, Bucheon, Korea
    Hepatogastroenterology 59:1168-73. 2012
    ..We evaluated the usefulness of cystatin C as a prognostic marker in patients with liver cirrhosis and normal serum creatinine...
  72. ncbi Management of refractory ascites and hepatorenal syndrome
    Anuchit Chutaputti
    Section of Digestive and Liver Diseases, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand
    J Gastroenterol Hepatol 17:456-61. 2002
    Refractory ascites and hepatorenal syndrome (HRS) are the late complications of the terminal stages of cirrhosis...
  73. ncbi Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome?
    Sambit Sen
    Gastroenterology 123:2160-1. 2002
  74. ncbi Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome
    Søren Møller
    Department of Clinical Physiology 239, Hvidovre Hospital, University of Copenhagen, DK 2650, Hvidovre, Denmark
    Scand J Gastroenterol 40:491-500. 2005
    b>Hepatorenal syndrome (HRS) is a functional and reversible impairment of renal function in patients with severe cirrhosis...
  75. ncbi Which patients benefit from hemodialysis therapy in hepatorenal syndrome?
    Oliver Witzke
    Department of Nephrology, University Clinic Essen, Essen, Germany
    J Gastroenterol Hepatol 19:1369-73. 2004
    b>Hepatorenal syndrome (HRS) occurs in patients with advanced liver cirrhosis and has a poor outcome. The aim of the present study was to investigate which patients with HRS are likely to benefit from hemodialysis.
  76. ncbi New challenge of hepatorenal syndrome: prevention and treatment
    F Wong
    Division of Gastroenterology, Department of Medicine, The Toronto General Hospital, University of Toronto, Ontario, Canada
    Hepatology 34:1242-51. 2001
    b>Hepatorenal syndrome (HRS) remains one of the major therapeutic challenges in hepatology today...
  77. ncbi Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
    M Guevara
    Liver Unit, Hospital Clinic i Provincial, University of Barcelona, Catalunya, Spain
    Hepatology 27:35-41. 1998
    b>Hepatorenal syndrome is caused by a marked vasoconstriction of the renal circulation...
  78. ncbi Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico
    Linda E Muñoz
    Liver Unit, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
    Ann Hepatol 8:207-11. 2009
    Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with type 1 HRS.
  79. ncbi Prometheus--a new extracorporeal system for the treatment of liver failure
    Kinan Rifai
    Division of Gastroenterology, Hepatology and Endocrinology, Department of Internal Medicine, Medical School Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    J Hepatol 39:984-90. 2003
    ..In a simultaneous step, high-flux hemodialysis is performed. We assessed safety, adsorber efficiency and clinical efficacy of the Prometheus system...
  80. ncbi Treatment of hepatorenal syndrome
    Tyree H Kiser
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80045, USA
    Pharmacotherapy 29:1196-211. 2009
    b>Hepatorenal syndrome (HRS) is a type of renal failure that occurs in patients with advanced cirrhosis...
  81. ncbi Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2
    Carlo Alessandria
    Department of Gastroenterology, San Giovanni Battista Hospital, Torino, Italy
    Eur J Gastroenterol Hepatol 14:1363-8. 2002
    Renal failure secondary to hepatorenal syndrome or to organic renal disease occurs frequently in cirrhotic patients with portal hypertension...
  82. ncbi Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience
    Xiao Xu
    Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
    Transplantation 87:1514-9. 2009
    Patients with hepatorenal syndrome (HRS) type 1 have an extremely poor prognosis. Liver transplantation (LT) is the only treatment that can cure terminal stage liver disease and reverse HRS...
  83. ncbi Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials
    Fabrizio Fabrizi
    Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS Foundation, Milan Italy
    Int J Artif Organs 32:133-40. 2009
    b>Hepatorenal syndrome (HRS) is a severe complication of end-stage renal disease whose management still constitutes a big challenge. Various approaches have been used for hepatorenal syndrome treatment, including vasoconstrictor therapy...
  84. ncbi Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients
    L Dagher
    Department of Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, London, UK
    Aliment Pharmacol Ther 14:515-21. 2000
    ..Where there is no anatomical or pathological cause for the renal failure, it is termed the hepatorenal syndrome. When the hepatorenal syndrome develops, it will only recover when there is some degree of improvement in ..
  85. ncbi Hepatorenal syndrome
    Deepak Venkat
    Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH 43210, USA
    South Med J 103:654-61. 2010
    Acute kidney injury (AKI) secondary to hepatorenal syndrome (HRS) is an ominous complication of end-stage liver disease (ESLD)...
  86. ncbi Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome
    André Nazar
    Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalunya, Spain
    Hepatology 51:219-26. 2010
    Terlipressin plus albumin is an effective treatment for type 1 hepatorenal syndrome (HRS), but approximately only half of the patients respond to this therapy...
  87. ncbi Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system
    S R Mitzner
    Department of Medicine, University of Rostock, Germany
    Ther Apher 5:417-22. 2001
    Recently, significant improvement of renal function and prolongation of survival were reported in hepatorenal syndrome (HRS) patients treated with the Molecular Adsorbent Recirculating System (MARS)...
  88. ncbi Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome
    J Salo
    Department of Medicine, Hospital Clinic i Provincial, Barcelona, Spain
    J Hepatol 25:916-23. 1996
    Intravenous ornipressin in cirrhotic patients with hepatorenal syndrome causes marked improvement of systemic hemodynamics and suppression of plasma renin and norepinephrine but only moderate improvement of renal function...
  89. ncbi Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study
    Tea Restuccia
    Liver Unit, Institute for Digestive Diseases, Hospital Clinic, University of Barcelona, Villarroel 170, Barcelona 08036, Catalunya, Spain
    J Hepatol 40:140-6. 2004
    Pretransplant renal function is the major determinant of survival after liver transplantation (LTx). Patients with hepatorenal syndrome (HRS) have a poor outcome after LTx compared with patients transplanted without HRS.
  90. ncbi Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations
    I Park
    Department of Nephrology, Ajou University School of Medicine, Suwon, Gyeonggi Do, Republic of Korea
    Transplant Proc 42:2563-6. 2010
    b>Hepatorenal syndrome (HRS) is a reversible, functional renal failure that occurs in patients with advanced hepatic failure...
  91. ncbi Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment
    Florence Wong
    Division of Gastroenterology, Department of Medicine, University of Toronto, 9N 983 Toronto General Hospital, 200 Elizabeth Street, Toronto M5G 2C4, Ontario, Canada
    Gut 59:381-6. 2010
    The pathogenetic mechanism of hepatorenal syndrome (HRS) is paradoxical renal vasoconstriction consequent upon systemic and splanchnic arterial vasodilatation...
  92. ncbi TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update
    Martin Rossle
    Praxiszentrum, Bertoldstrasse 48, Freiburg, Germany
    Gut 59:988-1000. 2010
    Refractory ascites is a frequent complication of advanced cirrhosis and is associated with hepatorenal syndrome and hepatic hydrothorax...
  93. ncbi Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study
    Gilles Pomier-Layrargues
    Liver Unit, Hopital Saint Luc, Centre Hospitalier de l Universite de Montreal, Montreal, Canada
    Hepatology 38:238-43. 2003
    The hepatorenal syndrome (HRS) is related to vasoconstriction of the renal cortex induced by systemic hypovolemia that follows splanchnic vasodilatation as the primary event in the cascade of hemodynamic changes associated with portal ..
  94. ncbi Hepatorenal syndrome: an update
    Tercio Genzini
    HEPATO, Hospital Beneficiencia Portuguesa, Sao Paulo, Brazil
    Sao Paulo Med J 125:50-6. 2007
    b>Hepatorenal syndrome (HRS) is the development of renal failure in patients with chronic previous liver disease, without clinical or laboratory evidence of previous kidney disease...
  95. ncbi Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials
    Sashidhar V Sagi
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    J Gastroenterol Hepatol 25:880-5. 2010
    b>Hepatorenal syndrome (HRS) is a serious complication of advanced liver disease and carries a poor prognosis. Recent trials have indicated that terlipressin may be effective in reversing HRS...
  96. ncbi Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis
    Isabelle Colle
    Laboratoire d Hémodynamique Splanchmique et de Biologie Vasculaire, Institut National de la Santé et de la Recherge Médicale, Clinchy, France
    J Gastroenterol Hepatol 17:882-8. 2002
    Terlipressin has been proposed to treat renal failure in patients with type 1 hepatorenal syndrome (HRS)...
  97. ncbi Rift Valley fever hepatitis complicated by disseminated intravascular coagulation and hepatorenal syndrome
    Tarig S Al-Khuwaitir
    Department of Medicine, Riyadh Medical Complex, Riyadh, Kingdom of Saudi Arabia
    Saudi Med J 25:528-31. 2004
  98. ncbi Hepatorenal syndrome: current diagnostic and therapeutic concepts
    Michael Schepke
    Department of Internal Medicine I, General Internal Medicine, University of Bonn, Germany
    Nephrol Dial Transplant 22:viii2-viii4. 2007
  99. ncbi Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome
    Vicente Arroyo
    Liver Unit, Institute of Digestive and Metabolic Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain
    J Hepatol 46:935-46. 2007
  100. ncbi Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study
    J P Mulkay
    Department of Gastroenterology, Hopital Erasme, , Brussels, Belgium
    Acta Gastroenterol Belg 64:15-9. 2001
    BACKGROUND: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis. Recently, ornipressin, a potent splanchnic vasoconstrictor, was reported to improve renal function in patients with HRS...
  101. ncbi [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]
    V Gulberg
    Medizinische Klinik II, Ludwig Maximilians Universitat, Munchen
    Z Gastroenterol 36:1053-8. 1998
    ..So far, no noninvasive therapy of hepatorenal syndrome has been established...

Research Grants20

  1. PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURE
    Ravindra Mehta; Fiscal Year: 2001
    ..It is anticipated (by the applicants) that information gained from this study, being largely observational, will be used to rationally design intervention strategies in future years. ..
  2. Predicting the burden of renal disease among liver transplant recipients
    Pratima Sharma; Fiscal Year: 2013
    ..from slight elevation in serum creatinine from pre-existing renal disease to full blown renal failure from hepatorenal syndrome requiring renal replacement therapy (RRT)...
  3. Novel therapies in alcoholic hepatitis University of Louisville
    Craig J McClain; Fiscal Year: 2013
    ..Studies on pentoxifylline in AH are limited, and efficacy appears highest in preventing/treating the hepatorenal syndrome. Thus, new therapies as well as a better understanding of mechanisms/biomarkers for severity of disease and ..
  4. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Jackson Roberts; Fiscal Year: 2010
    ..Finally, we will test the hypothesis that free radicals and IsoPs play an important role in the renal failure that ensues in glactosamine treated rats, an animal model of the hepatorenal syndrome.
  5. Quantitative Hemodynamics of the Liver with 4D Flow MRI
    Oliver Wieben; Fiscal Year: 2013
    ..the development of portosystemic collaterals (varices) that shunt blood from the liver, renal dysfunction (hepatorenal syndrome), accumulation of ascites, among other complications...
  6. Outpatient treatment for portal hypertension
    Elijah M Bolotin; Fiscal Year: 2010
    ..to prevent the development of life-threatening consequences, including bleeding esophageal varices and hepatorenal syndrome (HRS), pharmacological treatment options are severely limited...
  7. Liver Derived Microparticles In Cirhossis Pathogenesis
    RAFAL WITEK; Fiscal Year: 2009
    ..including cutaneous spider telangectases, cachexia, increased intestinal permeability, ascites and the hepatorenal syndrome, the portopulmonary syndrome, and hepatic encephalopathy...
  8. Identifying acute tubular necrosis in cirrhosis patients with renal dysfunction
    Chirag R Parikh; Fiscal Year: 2010
    ..In these cases, the main differential is between type 1 hepatorenal syndrome (HRS) and acute tubular necrosis (ATN)...
  9. STRUCTURAL IDENTIFICATION OF PROSTAGLANDIN CONJUGATES
    L Roberts; Fiscal Year: 2000
    ..The role of free radicals and IsoP's in mediating the renal dysfunction in an animal model of the hepatorenal syndrome will also be explored...
  10. IMMUNOASSAY FOR A NON-ENZYMATIC ARACHIDONATE DERIVATIVE
    KRISHNAMOORTHY SANKARAN; Fiscal Year: 1993
    ..significant diagnostic potential for the assessment of oxidative stress and in specific disorders such as hepatorenal syndrome, rheumatoid arthritis, and carcinogenesis. Isoprostanes have thus far been detected by mass spectrometry...
  11. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2008
    ..The studies will clarify why expression of certain proteins fall during the acute phase response. ..
  12. Biliary Microlithiasis in Alcohol Induced Pancreatitis
    Arun Sanyal; Fiscal Year: 2007
    ..The long-term goal is to use data from this R21 proposal to develop a RO1 proposal about a large scale phase III clinical trial of UDCA for alcohol-induced pancreatitis. [unreadable] [unreadable] [unreadable]..
  13. Epidemiology and Impact of Hepatitis C in the Community
    W Ray Kim; Fiscal Year: 2007
    ..abstract_text> ..
  14. Digoxin Chiral Isolates as Improved Pharmaceuticals
    John Somberg; Fiscal Year: 2005
    ..The advantage would be a treatment for AF that did not cause cardiac augmentation and vasoconstriction or a treatment for CHF that does not cause heart rate slowing or conduction disturbances. ..
  15. Pheresis Treatment of Bioterrorism-Induced Sepsis
    Stephen Ash; Fiscal Year: 2005
    ..The safety systems of the existing PF system will be modified to meet the needs of the stand-alone system. Finally, an animal model of sepsis will be used to check efficacy and safety of the entire system. ..
  16. IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERS
    Kelly Gebo; Fiscal Year: 2005
    ..Gebo the skills she needs to develop into an independent clinician researcher in HIV epidemiologic and health services research. ..
  17. CLINICAL OUTCOMES IN ELDERLY HIV PATIENTS
    Kelly Gebo; Fiscal Year: 2007
    ..abstract_text> ..
  18. MethLock vs. heparin as dialysis catheter lock
    Stephen Ash; Fiscal Year: 2008
    ..In Phase II we will implement the protocol in a number of dialysis centers and complete the study as originally proposed or as modified after Phase I. ..